Hemanext

Initiation of patient treatments in a randomized, controlled trial comparing hypoxic to conventional red blood cells for transfusion-dependent hematological malignancy patients.

Entered distribution agreement with Hemara Bio for commercial entry into UAE, Qatar, Kuwait, and Saudi Arabia.

U.S. Centers for Medicare & Medicaid Services assigned distinct reimbursement code facilitating hospital billing for hypoxic RBC units.

Post-market study completed in Norway evaluating safety of hypoxic RBC transfusion in patients with hematologic malignancies and acute burns.

Received FDA De Novo marketing authorization, enabling commercial distribution of the oxygen-controlled blood storage system in the U.S.

Ongoing clinical enrollment in Italy and Norway, including thalassemia and hematologic malignancy cohorts.

First clinical use of oxygen-controlled stored red blood cells initiated in Europe.

Collaboration to support patient education and awareness for sickle cell disease through community-focused programs.

Achieved CE mark for the red blood cell storage system, supporting commercial sales across Europe.